@melaniespeed's salmon DNA injection warning, fact-checked

What does this video actually claim?

Melanie Speed warns against injecting exosomes, salmon DNA (PDRN), and peptides because they lack FDA approval and sufficient safety research. She recommends using these substances topically with microneedling or laser treatments instead.

The video targets trending aesthetic treatments that she considers risky when injected. Speed positions herself as taking a cautious approach by avoiding injectable forms of these compounds at her practice.

Does the science back up her safety concerns?

Speed's caution about injectable exosomes and salmon DNA is well-founded. The FDA hasn't approved these for injection, and clinical data remains limited.

For PDRN (salmon DNA), most published studies focus on wound healing applications in controlled medical settings. A 2020 systematic review by Ronfard et al. in Wound Repair and Regeneration found promising results for wound treatment, but aesthetic injection studies are scarce. The quality control and sourcing of PDRN products varies widely between manufacturers.

Exosome injections pose particular risks since these extracellular vesicles can carry unknown biological materials. The FDA issued multiple warning letters to clinics promoting exosome treatments without proper approval.

What did she get wrong about peptides?

Speed lumps all peptides together, which oversimplifies a complex category. Some peptides do have established safety profiles when used appropriately.

GHK-Cu, for instance, has been studied extensively. A 2018 review by Pickart et al. in BioMed Research International documented its safety in topical applications over decades. However, Speed's broader point about injectable peptide risks holds water since most aesthetic peptide injections lack rigorous clinical trials.

Many peptide products sold for aesthetic use aren't manufactured under FDA oversight, creating quality control issues that Speed doesn't specifically mention but are relevant to her safety argument.

Is topical application really safer?

Speed's recommendation for topical use with microneedling makes sense from a risk perspective, though the efficacy claims need scrutiny.

Topical application does reduce systemic exposure risks compared to injection. Microneedling can enhance penetration without the complications of direct injection. However, the actual clinical benefits of topical PDRN or exosomes remain largely unproven.

A 2019 study by Kim et al. in Dermatologic Surgery showed modest improvements with topical PDRN after microneedling, but the results were measured primarily through patient satisfaction scores rather than objective metrics. The treatment showed benefits, but calling it definitively effective overstates the current evidence.

What should you actually know?

Speed gets the regulatory landscape right. These treatments exist in a gray area where clinics offer them despite limited FDA oversight and safety data.

The real issue isn't whether these compounds have potential benefits, but whether the current products and protocols have adequate safety testing. Many clinics source these materials from compounding pharmacies or overseas suppliers with variable quality standards.

If you're considering these treatments, ask specific questions about sourcing, manufacturing standards, and what adverse events the provider has seen. Speed's conservative approach reflects good medical practice when dealing with unproven interventions. The aesthetic medicine field has a track record of adopting treatments before adequate safety data exists.